Items Tagged ‘ado-trastuzumab’

August 30, 2017

FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer


The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer who have been treated with Herceptin and Perjeta and have disease progression after ado-trastuzumab (T-DM1). Breakthrough Therapy designation is designed to […]

View full entry

Tags: ado-trastuzumab, Breast Cancer, DS-8201, HER2-positive, herceptin, locally advanced, Metastatic Breast Cancer, News, perjeta, Precision Cancer Medicine, T-DM1